ライフサイエンスコーパス: high-grade prostate cancer

1 otential risks (including the possibility of high-grade prostate cancer).

2 men with systemic progression and death from high grade prostate cancer.

3 or SAPC as a potential prognostic marker for high grade prostate cancer.

4 ovel gene whose expression is inactivated in high grade prostate cancer.

5 gnosis of low-risk and the underdiagnosis of high-grade prostate cancer.

6 3.0% and 73.6%, respectively, for those with high-grade prostate cancer.

7 also associated with increased detection of high-grade prostate cancer.

8 n-7, could be involved in the development of high-grade prostate cancer.

9 hived specimens from untreated patients with high-grade prostate cancer.

10 There was no increase in high-grade prostate cancer.

11 enic, and eicosapentaenoic acids and risk of high-grade prostate cancer.

12 pendently associated with risk of lethal and high-grade prostate cancer.

13 d with decreased risk of prostate cancer and high-grade prostate cancer.

14 frequent allelic loss and downregulation in high-grade prostate cancer.

15 exual side effects and the increased risk of high-grade prostate cancer.

16 with an increased risk of advanced-stage and high-grade prostate cancer.

17 y end point was the incidence of adjudicated high-grade prostate cancer.

18 c alterations of KLF6 occur in a minority of high-grade prostate cancers.

19 expression is dramatically down-regulated in high grade prostate cancers (4/4) but is unaltered in lo

20 person-years of follow-up, the incidence of high-grade prostate cancer (5 of 2596 [0.19%] in the TRT

21 e 270, 148, and 88 cases of total, low-, and high-grade prostate cancers among African American men a

22 ification of both alternative treatments for high-grade prostate cancers and new biomarkers to predic

23 rmethylation is enriched in intermediate- to high-grade prostate cancers and not detectable in benign

24 at correlates with the likelihood of finding high grade prostate cancer at biopsy.

25 risk-stratify patients with intermediate- or high-grade prostate cancer before prostatectomy based on

26 ty is associated with an increase in risk of high-grade prostate cancer but with a decrease in risk o

27 proanthocyanidins (P for trend = 0.04) with high-grade prostate cancer, but not with advanced prosta

28 Rather, there was improved detection of high-grade prostate cancer due to decreased prostate vol

29 g; these findings were highly suspicious for high-grade prostate cancer (Fig 1).

30 hould be weighed with the potential risks of high-grade prostate cancer from 5-ARIs (although the maj

31 stry analysis revealed elevation of PROS1 in high grade prostate cancer (Gleason grade >/= 8), and fu

32 ade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.

33 index was positively associated with risk of high-grade prostate cancer in both non-Hispanic white me

34 n the BCPT) or apparent risk of finasteride (high-grade prostate cancer in the PCPT).

35 ncidence (HR, 1.02; 95% CI, 0.96 to 1.08) or high-grade prostate cancer incidence (HR, 0.91; 95% CI,

36 Lethal progression of high-grade prostate cancer occurred predominantly early,

37 nearly and inversely associated with risk of high-grade prostate cancer (quartile 4 vs. 1: TFA 18:1,

38 ds, flavan-3-ols, and proanthocyanidins with high-grade prostate cancer risk varied by follow-up time

39 and vitamin D intake and total, advanced, or high-grade prostate cancer risk, whether for total intak

40 vidually both for high stage (RR = 2.23) and high grade prostate cancer (RR = 1.89).

41 rved its significant (p < 0.05) elevation in high grade prostate cancer seminal plasma samples.

42 ARA70 expression is also increased in high-grade prostate cancer tissues as well as the hormon

43 may be associated with an increased risk of high-grade prostate cancer tumors that would ultimately

44 Hsp27 and Twist expression each elevated in high-grade prostate cancer tumors.

45 High-grade prostate cancer was more common in the finast

46 oreactivity was significantly upregulated in high-grade prostate cancer when compared to benign prost

47 men with a new diagnosis of intermediate- or high-grade prostate cancer who were candidates for prost

48 ferentiating low-grade from intermediate- or high-grade prostate cancer with diffusion-weighted MR im

49 Patients with high-grade prostate cancer with low levels of prostate-s

50 Outcomes are also disparate among men with high-grade prostate cancer, with upwards of 65% having d